Characterization of the Surface Marker ROR1 as a potential Target of CAR-T Cell Therapy in anaplastic Thyroid Carcinoma

被引：0
|
作者：
Skorobohatko, O. [1 ]
Chernyakov, D. [1 ]
Edemir, B. [1 ]
Nerger, K. [1 ]
Binder, M. [1 ]
Trojanowicz, B. [2 ]
Lorenz, K. [2 ]
Huttelmaier, S. [3 ]
Alb, M. [4 ]
Hudecek, M. [4 ]
Dierks, C. [1 ]
机构：
[1] Univ Klinikum Halle Saale, Innere Med 4, Halle, Germany
[2] Univ Klinikum Halle Saale, Viszerale Gefass & Endokrine Chirurg, Halle, Germany
[3] Inst Mol Med, Arbeitsgruppe Mol Zellbiol, Halle, Germany
[4] Univ Wurzburg, Innere Med 4, Wurzburg, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V482
引用
收藏
页码：155 / 156
页数：2
相关论文
共 50 条
  • [1] Characterization of the surface marker ROR1 as a potential target of CAR-T cell therapy in anaplastic thyroid carcinoma
    Skorobohatko, O.
    Chernyakov, D.
    Braeuer-Hartmann, D.
    Mueller, T.
    Wehde, J.
    Trojanowicz, B.
    Alb, M.
    Hudecek, M.
    Lorenz, K.
    Dierks, C.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 198 - 198
  • [2] ROR1-CAR T-CELLS AS NOVEL TREATMENT STRATEGY FOR ANAPLASTIC THYROID CARCINOMA
    Chernyakov, D.
    Skorobohatko, O.
    Edemir, B.
    Nerger, K.
    Mueller, T.
    Binder, M.
    Trojanowicz, B.
    Lorenz, K.
    Huettelmaier, S.
    Alb, M.
    Hudecek, M.
    Dierks, C.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A22 - A23
  • [3] Developing ROR1 Targeting CAR-T Cells against Solid Tumors in Preclinical Studies
    Lee, Boon Kiat
    Wan, Yuhua
    Chin, Zan Lynn
    Deng, Linyan
    Deng, Mo
    Leung, Tze Ming
    Hua, Jian
    Zhang, Hua
    [J]. CANCERS, 2022, 14 (15)
  • [4] NOVEL TARGET ANTIGENS FOR CAR-T CELL THERAPY
    Perriello, V. M.
    Falini, B.
    [J]. HAEMATOLOGICA, 2022, 107 : 11 - 12
  • [5] Profiling targets and potential target pairs of CAR-T cell therapy in clinical trials
    Zhang, Daiyan
    Lyu, Liyang
    Han, Shuo
    Xu, Jiaqi
    Hu, Guang
    Zhao, Qi
    Hu, Yuanjia
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 126
  • [6] ROR1-targeting switchable CAR-T cells for cancer therapy
    Haiyong Peng
    Thomas Nerreter
    Katrin Mestermann
    Jakob Wachter
    Jing Chang
    Michael Hudecek
    Christoph Rader
    [J]. Oncogene, 2022, 41 : 4104 - 4114
  • [7] ROR1-targeting switchable CAR-T cells for cancer therapy
    Peng, Haiyong
    Nerreter, Thomas
    Mestermann, Katrin
    Wachter, Jakob
    Chang, Jing
    Hudecek, Michael
    Rader, Christoph
    [J]. ONCOGENE, 2022,
  • [8] ROR1-targeting switchable CAR-T cells for cancer therapy
    Peng, Haiyong
    Nerreter, Thomas
    Mestermann, Katrin
    Wachter, Jakob
    Chang, Jing
    Hudecek, Michael
    Rader, Christoph
    [J]. ONCOGENE, 2022, 41 (34) : 4104 - 4114
  • [9] Overcoming Target Driven Fratricide for CAR-T Cell Therapy
    Sotiropoulou, Panagiota A.
    Breman, Eytan
    Demoulin, Benjamin
    Agaugue, Sophie
    Mauen, Sebastien
    Michaux, Alexandre
    Springuel, Lorraine
    Houssa, Julien
    Huberty, Fanny
    Jacques-Hespel, Celine
    Marchand, Celine
    Marijsse, Jerome
    Thuy Nguyen
    Ramelot, Nancy
    Daro, Dorothee
    DeWaele, Peter
    Steenwinckel, Valerie
    Gilham, David
    [J]. MOLECULAR THERAPY, 2018, 26 (05) : 57 - 58
  • [10] LYL797, a ROR1 CAR T-cell therapy with genetic and epigenetic reprogramming for solid tumors
    Park, Spencer
    Simianer, Courtney
    Spadinger, Sydney
    Wang, Xiao
    Sundar, Purnima
    Potluri, Shobha
    Lynn, Rachel
    Boldajipour, Bijan
    Wang, Grace
    Sharma, Neeraj
    Hiraragi, Hajime
    Krishnamoorthy, Veena
    Vodnala, Suman Kumar
    Ong, E-Ching
    Wu, Chang-Chih
    Wohlfahrt, Martin
    Ryu, Byoung
    Song, Lisa
    Weitzner, Brian D.
    Moffett, Howell
    Lajoie, Marc
    Boyken, Scott
    Shabaneh, Tamer
    Srivastava, Shivani
    Albertson, Tina
    Sather, Blythe
    [J]. CANCER RESEARCH, 2022, 82 (12)
12345